论文部分内容阅读
近年,由于研制出新的抗菌剂,使尿路感染的治疗效果不断提高。但对于绿脓杆菌导致的尿路感染,却不能收到满意的疗效,往往治疗艰涩。目前,对抗绿脓杆菌的抗菌剂之一,具有特异性抗菌力的头孢磺吡苄(CFS),虽市售且广泛地被应用,但由于绿脓杆菌所致尿路感染多系合并其它细菌感染,所以即使给与CFS,也易于残留共存菌,还会遗留下给药后菌群交替率高等问题。基于上述因素,作者以疑为难治性绿脓杆菌感染的复杂性尿路感染患者为对象,采取头孢氨噻肟唑
In recent years, due to the development of new antibacterial agents, the treatment of urinary tract infections continue to improve. However, for the urethra caused by Pseudomonas aeruginosa infection, but can not receive satisfactory results, often treated astringent. At present, one of the antibacterial agents against Pseudomonas aeruginosa, cefazipirone (CFS) having specific antimicrobial activity, is commercially available and widely used. However, urinary tract infections due to Pseudomonas aeruginosa are mostly associated with other bacteria Infection, so even with CFS, but also easy to residual coexistence of bacteria, but also left behind after the administration of bacteria and other issues of high turnover rate. Based on the above factors, the author of the complex refractory Pseudomonas aeruginosa infection in patients with urinary tract infection as the object, taking ceftazidimethoxazole